506 related articles for article (PubMed ID: 24650691)
21. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
22. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
23. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
24. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
[TBL] [Abstract][Full Text] [Related]
26. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
[TBL] [Abstract][Full Text] [Related]
27. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia.
Warren E; Wright A; Jones B
Value Health; 2014 Dec; 17(8):792-800. PubMed ID: 25498774
[TBL] [Abstract][Full Text] [Related]
29. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.
Gimeno-Ballester V; Mar J; O'Leary A; Adams R; San Miguel R
Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):85-93. PubMed ID: 27500437
[TBL] [Abstract][Full Text] [Related]
31. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
32. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
[TBL] [Abstract][Full Text] [Related]
33. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
34. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
[TBL] [Abstract][Full Text] [Related]
35. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective.
Borba HHL; Rochau U; Wiens A; Sroczynski G; Siebert U; Ferreira VL; Minowa E; Pontarolo R
Value Health Reg Issues; 2019 Dec; 20():95-102. PubMed ID: 31108456
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.
Gomes LO; Teixeira MR; Rosa JAD; Feltrin AA; Rodrigues JPV; Vecchi MD; Carneiro JMM; Noblat LACB; Chachá SGF; Martinelli ALC; Pereira LRL; Silveira MPT; Blatt CR; Farias MR
Rev Inst Med Trop Sao Paulo; 2018; 60():e29. PubMed ID: 29972466
[TBL] [Abstract][Full Text] [Related]
38. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
Linas BP; Barter DM; Leff JA; DiLorenzo M; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Kim AY; Freedberg KA
AIDS; 2014 Jan; 28(3):365-76. PubMed ID: 24670522
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
40. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
Ji D; Chen GF; Wang C; Wang YD; Shao Q; Li B; Zhao J; You SL; Hu JH; Liu JL; Niu XX; Chen J; Lu L; Wu V; Lau G
Hepatol Int; 2016 Sep; 10(5):789-98. PubMed ID: 27443347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
